

Supplementary data

The antibodies and panel design used in this study. A panel consisted of 1 or more staining tubes

Panel	Staining tube	Conjugate	Titer	Stock (µg/µL)	Clone	Company
Lymphocytes						
	Staining tube 1					
	T-cells	CD3-PE	1:200	0.2	17A2	BioLegend
	T-killer	CD8-PacOr	1:100	0.1	5H10	Life Technologies
	Myeloid cells	Gr-1-PECy5	1:640	0.2	RB6-8C5	BioLegend
	Signaling	CD200-APC	1:100	0.2	OX-90	BioLegend
	Leukocytes	CD45-FITC	1:200	0.5	30-F11	BioLegend
	B-cells	CD19-APC-Cy7	1:100	0.2	6D5	BioLegend
	Staining tube 2					
	Activated T-helper	CD25-PECy7	1:200	0.2	PC61	BioLegend
	T-cells	CD3-V500	1:200	0.2	500A2	BD
	T-helper	CD4-PERCPCy5.5	1:200	0.2	RM4-5	BioLegend
	Leukocytes	CD45-APC	1:100	0.2	30-F11	BioLegend
	NK-cell	NK1.1-FITC	1:400	0.5	PK136	BioLegend
Macrophages						
	Staining tube 1					
	Leukocytes	CD45-APC	1:100	0.2	30-F11	BioLegend
	T-cells	CD3-PE	1:200	0.2	17A2	BioLegend
	Myeloid cells	CD11b-V500	1:200	0.2	M1/70	BD
	M1	CCR7-PERCPCy5.5	1:20	0.5	4B12	BioLegend
	CD200 receptor	CD200R-FITC	1:50	0.5	OX-110	BioLegend
	Staining tube 2					
	Leukocytes	CD45-FITC	1:200	0.5	30-F11	BioLegend
	B-cells	CD19-APCCy7	1:100	0.2	6D5	BioLegend
	M2	CD206-AF467	1:100	0.5	C068C2	BioLegend
	Myeloid cells	CD11b-V500	1:200	0.2	M1/70	BD
	Myeloid cells	Gr-1-PacOr	1:320	0.1	RB6-8C5	Life Technologies
	Staining tube 3					
	Leukocytes	CD45-FITC	1:200	0.5	30-F11	BioLegend
	Myeloid cells	CD11b-V500	1:200	0.2	M1/70	BD
	Monocytes	CD14-APC-Cy7	1:40	0.2	Sa14-2	BioLegend
	M1	CD86-PE-Cy5	1:100	0.2	GL-1	BioLegend
Sham						
	Staining tube 1					
	Leukocytes	CD45-FITC	1:200	0.5	30-F11	BioLegend
	T-cells	CD3-PE	1:200	0.2	17A2	BioLegend
	Myeloid cells	CD11b-V500	1:200	0.2	M1/70	BD
	T-helper	CD4-PERCPCy5.5	1:200	0.2	RM4-5	BioLegend
	B-cells	CD19-PE-Cy5	1:100	0.2	RM4-5	BioLegend
	T-killer	CD8-PacOr	1:100	0.1	5H10	Life Technologies
	Monocytes	CD14-APC-Cy7	1:40	0.2	Sa14-2	BioLegend
	NK-cell	NK1.1-AF700	1:400	0.5	PK136	BioLegend








Figure S1. Flow diagram of study design. The panels refer to panels of antibodies as disclosed in Table 1.




A




B





E



F

Figure S2 A-F. Dot plots from one tissue sample from an uninjured mouse. The staining design included five different staining tubes as can be seen in the table of antibodies and the flow diagram. Beneath the sample dot plots are the corresponding FMOs A) All samples were first gated for singlet cells, scatter gate and living cells. This approach was the same for all samples. B) Lymphocyte panel, staining tube 1. C) Lymphocyte panel, staining tube 2. D) Monocyte panel, staining tube 1. E) Monocyte panel, staining tube 2. F) Monocyte panel, staining tube 3.




Figure S3. Same as figure 5 but with Bonferroni correction, meaning that the confidence intervals covers 99.8 % of the probability distribution of the mean.




Figure S4. Injured tibia vs contralateral tibia with cell types expressed as percentage of CD45+ cell count. The straight line marks the mean value of six observations from each mouse, and the dashed lines mark the 95% confidence interval.




Figure S5. Effect of sham surgery on immune populations 5 days after surgery. A smaller panel was used than in other experiments, but all major cell populations were studied.